

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number
WO 01/70686 A1

(51) International Patent Classification⁷: C07D 209/16,
A61K 31/40

[US/US]: 4132 Hildring Drive, Fort Worth, TX 76109
(US). ZINKE, Paul, W. [US/US]; 4129 Willow Way
Road, Fort Worth, TX 76133 (US).

(21) International Application Number: PCT/US00/31144

(22) International Filing Date:
14 November 2000 (14.11.2000)

(74) Agents: YEAGER, Sally, S. et al.; R & D Counsel, Mail
Code Q-148, 6201 South Freeway, Fort Worth, TX 76134
(US).

(25) Filing Language: English

(81) Designated States (*national*): AU, BR, CA, CN, JP, KR,
MX, PL, US, ZA.

(26) Publication Language: English

(30) Priority Data:
60/190,205 17 March 2000 (17.03.2000) US

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).

(71) Applicant (*for all designated States except US*): ALCON
UNIVERSAL LTD. [CH/CH]; P.O. Box 62, Bosch 60,
CH-6331 Hünenberg (CH).

Published:
— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): MAY, Jesse, A.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/70686 A1

(54) Title: 5-HYDROXY INDOLE DERIVATIVES FOR TREATING GLAUCOMA

(57) Abstract: Novel 3-(2-aminopropyl)-H-indol-5-ols useful for lowering and controlling IOP and treating glaucoma are disclosed.

5-HYDROXY INDOLE DERIVATIVES FOR TREATING GLAUCOMA

The present invention is directed to novel substituted 3-(2-aminopropyl)-1H-indol-5-ols. These novel compounds are useful for lowering and controlling normal or elevated intraocular pressure (IOP) and treating glaucoma.

Background of the Invention

The disease state referred to as glaucoma is characterized by a permanent loss of visual function due to irreversible damage to the optic nerve. The several morphologically or functionally distinct types of glaucoma are typically characterized by elevated IOP, which is considered to be causally related to the pathological course of the disease. Ocular hypertension is a condition wherein intraocular pressure is elevated but no apparent loss of visual function has occurred; such patients are considered to be a high risk for the eventual development of the visual loss associated with glaucoma. If glaucoma or ocular hypertension is detected early and treated promptly with medications that effectively reduce elevated intraocular pressure, loss of visual function or its progressive deterioration can generally be ameliorated. Drug therapies that have proven to be effective for the reduction of intraocular pressure include both agents that decrease aqueous humor production and agents that increase the outflow facility. Such therapies are in general administered by one of two possible routes, topically (direct application to the eye) or orally.

There are some individuals who do not respond well when treated with certain existing glaucoma therapies. There is, therefore, a need for other topical therapeutic agents that control IOP.

It has been found that serotonergic compounds which possess agonist activity at 5-HT₂ receptors effectively lower and control normal and elevated IOP and are useful for treating glaucoma, see commonly owned co-pending application, PCT/US99/19888. Compounds that act as agonists at 5-HT₂ receptors are known and have shown a variety of utilities, primarily for disorders or conditions associated with the central nervous system (CNS). U.S. Patent 5,494,928 discloses certain 2-(indol-1-yl)-ethylamine derivatives that are 5-HT_{2C} agonists for the treatment of obsessive compulsive disorder and other CNS derived personality disorders. U.S. Patent 5,571,833 discloses tryptamine derivatives that are 5-HT₂ agonists for the treatment of portal hypertension and migraine. U.S. Patent 5,874,477 discloses a method for treating malaria using 5-HT_{2A/2C} agonists. U.S. Patent 5,902,815 discloses the use of

5-HT_{2A} agonists to prevent adverse effects of NMDA receptor hypo-function. WO98/31354A2 discloses 5-HT_{2B} agonists for the treatment of depression and other CNS conditions. WO00/12475 discloses indoline derivatives as 5-HT_{2B} and 5-HT_{2C} receptor agonists for the treatment of a variety of disorders of the central nervous system, but especially for the treatment of obesity. WO00/35922 discloses certain pyrazino[1,2-*a*]quinoxaline derivatives as 5-HT_{2C} agonists for the treatment of obsessive-compulsive disorder, depression, eating disorders, and other disorders involving the CNS. Agonist response at the 5-HT_{2A} receptor is reported to be the primary activity responsible for hallucinogenic activity, with some lesser involvement of the 5-HT_{2C} receptor possible [Psychopharmacology, Vol. 121:357, 1995].

A specific disclosure in co-pending application PCT/US99/19888 relates to certain substituted α -methyltryptamines which are effective agents for lowering intraocular pressure in mammals (Table 1). However, when a phenolic moiety is included in this substitution, e.g. a hydroxyl group at indole ring position five such compounds can be particularly sensitive to oxidation reactions well known to occur with phenolic compounds in general, including hydroxytryptamines [*J. Phys. Chem.* 103, 8606 (1999), *Chem. Res. Toxicol.* 11, 639 (1998), *J. Org. Chem.* 52, 2817 (1987), *J. Pharm. Sci.* 77, 911 (1988)], which are of particular relevance to the present application. Protection of such hydroxy substituted tryptamines from oxidation can be accomplished by derivatization of the aryl hydroxy group to provide a suitable ester, carbamate, or carbonate. Though the ester, carbamate, or carbonate derivatives do not themselves possess a high affinity for the above mentioned receptors, they do have utility in the treatment of glaucoma since suitably protected phenols can be cleaved in vivo either by chemical hydrolysis or through the action of tissue esterases, thereby delivering the desired therapeutic agent, that is, the desired hydroxytryptamine compound in the present case. The concept of utilizing such derivatized phenolic compounds as chemical delivery agents is well known in the art [*Drugs Pharm. Sci.* 53, 221 (1992), *Pharm. Res.*, 168 (1984)].

Table 1. IOP Response in hypertensive cynomolgus monkeys.

Example	Dose, μ g	Baseline IOP (mmHg)	Percent IOP Reduction \pm SEM Hours after dose		
			1	3	6
α -Methylserotonin	250	41.8	14.2 \pm 4.39	25.8 \pm 5.16	30.8 \pm 7.72
Serotonin	250	33.5	13.3 \pm 5.31	18.0 \pm 5.12	2.0 \pm 7.39


Summary of the Invention

The present invention is directed to new derivatives of 3-(2-aminopropyl)-1*H*-indol-5-ol which can be used to lower and control IOP associated with normal-tension glaucoma, ocular hypertension, and glaucoma in warm blooded animals, including man. The compounds are formulated in pharmaceutical compositions suitable for topical delivery to the eye.

Description of the Preferred Embodiments

Compounds that are useful according to the present invention are represented by the following Formula I.

FORMULA I



Wherein G is chosen from hydrogen, halogen, or C₁₋₄alkyl;
R is chosen from C₃₋₆alkyl, C₃₋₆alkyl substituted with hydroxyl, CO(OC₁₋₄alkyl),
CON(C₁₋₄alkyl)₂, or C₂₋₄alkenyl substituted by phenyl;
R' is chosen from hydrogen, C₁₋₄alkyl;
and pharmaceutically acceptable salts and solvates of the compounds.

It is recognized that compounds of Formula I can contain one or more chiral centers. This invention contemplates all enantiomers, diastereomers and mixtures thereof.


In the above definitions, the total number of carbon atoms in a substituent group is indicated by the Ci-j prefix where the numbers i and j define the number of carbon atoms; this definition includes branched chain, and cyclic alkyl or (cyclic alkyl)alkyl groups.

It is important to recognize that a substituent may be present either singly or multiply when incorporated into the indicated structural unit. For example, the substituent halogen, which means fluorine, chlorine, bromine, or iodine, would indicate that the unit to which it is attached may be substituted with one or more halogen atoms, which may be the same or different.

SYNTHESIS


The compounds of Formula I can be readily prepared from, for example, α -methyl-5-hydroxy-tryptamine [*J. Med. Chem.* 33, 755 (1990), *J. Org. Chem.* 25, 1548 (1960)] or a desirably substituted derivative of structure 1 wherein G is as defined previously. That is, compounds of Formula I can be prepared by reacting the appropriate indole 1, or preferably a suitable amino-protected intermediate, e.g. 2 (Scheme 1) with the desired activated acid derivative, such as an acid halide or active ester, or the like, to provide the esters 3. Removal of the *N*-protective group from the intermediate 3 provides the desired compounds of Formula I.

Scheme 1



The indole derivatives of interest for use as starting materials for the preparation of 1 can be either purchased from commercial suppliers or prepared by well known methods [*Comp. Heterocycl. Chem.* II, Vol. 2:119, 1996; *Indoles*, Sundberg, 1996]. For example, one such approach begins with the desired 5-alkoxy-2-nitrotoluene 5 and proceeds via a Leimgruber-Batcho indole synthesis [*J. Med. Chem.* 22, 63 (1979) and U.S. Patent 3,732,245] to give the desired indoles 7 (Scheme 2). Intermediates 7 can be readily transformed into indoles 1 by well known methods [*J. Med. Chem.* 33, 755 (1990), *J. Org. Chem.* 25, 1548 (1960)].

Scheme 2



The compounds of this invention, Formula I, can be incorporated into various types of ophthalmic formulations for delivery to the eye (e.g., topically, intracamerally, or via an implant). The compounds are preferably incorporated into topical ophthalmic formulations for delivery to the eye. The compounds may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, and water to form an aqueous, sterile ophthalmic suspension or solution. Ophthalmic solution formulations may be prepared by dissolving a compound in a physiologically acceptable isotonic aqueous buffer. Further, the ophthalmic solution may include an ophthalmologically acceptable surfactant to assist in dissolving the compound. Furthermore, the ophthalmic solution may contain an agent to increase viscosity, such as, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinylpyrrolidone, or the like, to improve the retention of the formulation in the conjunctival sac. Gelling agents can also be used, including, but not limited to, gellan and xanthan gum. In order to prepare sterile ophthalmic ointment formulations, the active ingredient is combined with a preservative in an appropriate vehicle, such as, mineral oil, liquid lanolin, or white petrolatum. Sterile ophthalmic gel formulations may be prepared by suspending the active ingredient in a hydrophilic base prepared from the combination of, for example, carbopol-974, or the like, according to the published formulations for analogous ophthalmic preparations; preservatives and tonicity agents can be incorporated.

The compounds are preferably formulated as topical ophthalmic suspensions or solutions, with a pH of about 5 to 8. The compounds will normally be contained in these formulations in an amount 0.01% to 5% by weight, but preferably in an amount of 0.25% to 2% by weight. Thus, for topical presentation 1 to 2 drops of these formulations would be delivered to the surface of the eye 1 to 4 times per day according to the discretion of a skilled clinician.

The compounds can also be used in combination with other agents for treating glaucoma, such as, but not limited to, β -blockers (e.g., timolol, betaxolol,

levobetaxolol, carteolol, levobunolol, propranolol), carbonic anhydrase inhibitors (e.g., brinzolamide and dorzolamide), $\alpha 1$ antagonists (e.g. nipradolol), $\alpha 2$ agonists (e.g., iopidine and brimonidine), miotics (e.g., pilocarpine and epinephrine), prostaglandin analogs (e.g., latanoprost, travaprost, unoprostone, and compounds set forth in U.S. Patent Nos. 5,889,052; 5,296,504; 5,422,368; and 5,151,444, "hypotensive lipids" (e.g., lumigan and compounds set forth in 5,352,708), and neuroprotectants (e.g., compounds from U.S. Patent No. 4,690,931, particularly eliprodil and R-eliprodil, as set forth in a pending application U.S.S.N. 06/203350, and appropriate compounds from WO94/13275, including memantine.

The following examples are given to illustrate the preparation of compounds that are the subject of this invention but should not be construed as implying any limitations to the claims. The preferred compounds of Formula I are described in Examples 2-4. Especially preferred compounds are those set forth in Examples 3 and 4. The most preferred is the compound of Example 3. The proton magnetic resonance spectrum of each compound of the Examples was consistent with the assigned structure. All compounds had satisfactory HPLC analysis.

EXAMPLE 1

Propionic acid 3-(2-aminopropyl)-1*H*-indol-5-yl ester

Step A. [2-(5-Hydroxy-1*H*-indol-3-yl)-1-methylethyl]carbamic acid 9*H*-fluoren-9-ylmethyl ester

A 35 mL round bottom flask was charged with 3-(2-aminopropyl)-1*H*-indol-5-ol (0.20 g, 0.65 mmol) was added NaHCO₃ (0.9 g, 11 mmol), water (2 mL) and 1,4-dioxane (8 mL). 9-Fluorenylmethyl chloroformate (0.20 g, 0.82 mmol) was added and the mixture stirred for 16 h at 23°C. TLC analysis indicated that the reaction was complete and the solution decanted into aqueous NaHCO₃, then extracted with ether (2 x 30 mL). The combined organic extracts were washed with water (20 mL), dried over MgSO₄ and concentrated. The crude product was purified by chromatography (silica, 65:35 hexanes:ethyl acetate) to furnish the title compound (0.26 g, 97 %): ¹H NMR (CDCl₃) δ 7.88 (bs, 1H), 7.76 (d, J = 6 Hz, 2H), 7.57 (d, J = 6 Hz, 2H), 7.44-7.19 (m, 6H), 7.07 (s, 1H), 6.94 (s, 1H), 6.77 (dd, J = 8, 2 Hz, 1H), 4.8 (m, 1H), 4.45 (m, J = 8 Hz, 2H), 4.20 (m, J = 8 Hz, 1H), 2.81 (bm, 2H), 1.15 (d, J = 8 Hz, 3H); MS(ESI) *m/z* 430 (M + NH₄)⁺, 413 (M + H)⁺.

Step B. Propionic acid 3-[2-(9H-fluoren-9-ylmethoxycarbonylamino)propyl]-1H-indol-5-yl ester

A 25 mL round bottom flask fitted with magnetic stirring bar and septum inlet was charged with the product from Step A (0.24 g, 0.58 mmol), CH₂Cl₂ (10 mL), and diisopropylethyl amine (0.12 g, 0.9 mmol). Propionyl chloride (0.083 g, 0.9 mmol) was added followed by addition of DMAP (0.005g, 0.04 mmol). The solution was stirred for 14 h at 23°C, then poured into dilute aqueous NaHCO₃ and extracted with ether (2 x 20 mL). The combined extracts were dried (MgSO₄), filtered, and concentrated. The crude material was purified by chromatography (silica, 7:3 hexanes:ethyl acetate) to furnish the title compound (0.15 g, 55%): ¹H NMR (CDCl₃) δ 8.03 (bs, 1H), 7.76 (d, J = 6 Hz, 2H), 7.56 (d, J = 6 Hz, 2H), 7.43-7.29 (m, 7H), 6.99 (bs, 1H), 6.77 (dd, J = 8, 2 Hz, 1H), 4.43 (m, 1H), 4.37 (m, J = 8 Hz, 2H), 4.20 (m, J = 8 Hz, 1H), 2.84 (bm, 2H), 2.58 (q, J = 6 Hz, 2H), 1.25 (q, J = 6 Hz, 3H), 1.15 (d, J = 8 Hz, 3H); MS(ESI) *m/z* 486 (M + NH₄)⁺, 469 (M + H)⁺.

Step C: Propionic acid 3-(2-aminopropyl)-1H-indol-5-yl ester

A 10 mL round bottom flask fitted with magnetic stirring bar and septum inlet was charged with the product from Step B (0.14 g, 0.30 mmol), DMF (4 mL), and piperidine (1 mL, 0.9 mmol). The solution was stirred for 5 minutes, then poured into dilute aq. NaHCO₃ (1 mL) and extracted with ethyl acetate (3 x 10 mL), and CH₂Cl₂ (1 x 10 mL). The combined organic extracts were concentrated and the crude material purified by chromatography (silica, gradient, 10% to 50% MeOH in CH₂Cl₂) to provide the title compound (0.046 g, 63%): ¹H NMR (CDCl₃) δ 8.1 (bs, 1H), 7.31 (dd, J = 8, 2 Hz, 1H), 7.2 (s, 1H), 6.92 (d, J = 2 Hz, 1H), 6.85 (dd, J = 8, 2 Hz, 1H), 3.2 (m, 1H), 2.9 - 2.4 (m, 4H), 1.29 (t, J = 8 Hz, 3H), 1.17 (d, J = 8 Hz, 3H); MS(ESI) *m/z* 247 (M + H)⁺.

EXAMPLE 2**Isobutyric acid 3-(2-aminopropyl)-1H-indol-5-yl ester****Step A. Isobutyric acid 3-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-propyl]-1H-indol-5-yl ester**

Prepared as described in Example 1, Step B but using isobutyryl chloride: oil, 83% yield; ¹H NMR (CDCl₃) δ 8.05 (bs, 1H), 7.75 (d, J = 6 Hz, 2H), 7.54 (d, J = 6 Hz, 2H), 7.43-7.29 (m, 7H), 6.97 (bs, 1H), 6.87 (dd, J = 8, 2 Hz, 1H), 4.43 (m, 1H), 4.37 (m, J = 8 Hz, 2H), 4.20 (m, J = 8 Hz, 1H), 2.87 (bm, 2H), 2.73 (hept, J = 6 Hz, 1H), 1.25 (d, J = 6 Hz, 6H), 1.15 (d, J = 8 Hz, 3H); MS(ESI) *m/z* 500 (M + NH₄)⁺, 483 (M + H)⁺.

Step B. Isobutyric acid 3-(2-aminopropyl)-1H-indol-5-yl ester

Prepared from the product of Step A as described in Example 1, Step C: oil, 58% yield; ^1H NMR (CDCl_3) δ 8.2 (bs, 1H), 7.3 (d, $J = 8$ Hz, 1H), 7.2 (s, 1H), 7.0 (s, 1H), 6.85 (dd, $J = 8$, 2 Hz, 1H), 3.2 (m, 1H), 2.9 - 2.4 (m, 2H), 1.6 (m, 1H), 1.31 (d, $J = 6$ Hz, 6H), 1.17 (d, $J = 8$ Hz, 3H); MS(ESI) m/z 261 ($M + H$) $^+$.

EXAMPLE 3**2,2-Dimethyl-propionic acid 3-(2-aminopropyl)-1H-indol-5-yl ester****Step A. 2,2-Dimethyl-propionic acid 3-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-propyl]-1H-indol-5-yl ester**

Prepared as described in Example 1, Step B but using pivaloyl chloride: oil, 49% yield; ^1H NMR (CDCl_3) δ 8.05 (bs, 1H), 7.75 (d, $J = 6$ Hz, 2H), 7.54 (d, $J = 6$ Hz, 2H), 7.43-7.29 (m, 7H), 6.97 (bs, 1H), 6.87 (dd, $J = 8$, 2 Hz, 1H), 4.43 (m, 1H), 4.37 (m, $J = 8$ Hz, 2H), 4.20 (m, $J = 8$ Hz, 1H), 2.87 (bm, 2H), 1.6 (s, 9H), 1.15 (d, $J = 8$ Hz, 3H); MS(ESI) m/z 514 ($M + \text{NH}_4$) $^+$, 497 ($M + H$) $^+$.

Step B. 2,2-Dimethyl-propionic acid 3-(2-aminopropyl)-1H-indol-5-yl ester

Prepared from the product of Step A as described in Example 1, Step C: oil, 45% yield; ^1H NMR (CDCl_3) δ 8.1 (bs, 1H), 7.3 (d, $J = 8$ Hz, 1H), 7.2 (s, 1H), 7.0 (d, $J = 2.2$ Hz, 1H), 6.85 (dd, $J = 8$, 2 Hz, 1H), 3.2 (m, 1H), 2.8 (dd, $J = 14.2$, 4.8 Hz, 1H), 2.62 (dd, $J = 14.2$, 6.0 Hz, 1H), 1.39 (s, 9H), 1.17 (d, $J = 8$ Hz, 3H); MS(ESI) m/z 275 ($M + H$) $^+$.

EXAMPLE 4**Cyclopropanecarboxylic acid 3-(2-aminopropyl)-1H-indol-5-yl ester****Step A. Cyclopropanecarboxylic acid 3-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-propyl]-1H-indol-5-yl ester**

Prepared as described in Example 1, Step B but using cyclopropanecarbonyl chloride: oil, 57% yield; ^1H NMR (CDCl_3) δ 8.05 (bs, 1H), 7.76 (d, $J = 6$ Hz, 2H), 7.54 (d, $J = 6$ Hz, 2H), 7.43-7.29 (m, 7H), 6.97 (bs, 1H), 6.87 (dd, $J = 8$, 2 Hz, 1H), 4.7 (m, 1H), 4.4 (m, $J = 8$ Hz, 2H), 4.20 (m, $J = 8$ Hz, 1H), 4.0 (bs, 1H), 2.87 (bm, 2H), 1.8 (m, 1H), 1.7-1.1 (bm, 7H); MS(ESI) m/z 498 ($M + \text{NH}_4$) $^+$, 481 ($M + H$) $^+$.

Step B. Cyclopropanecarboxylic acid 3-(2-aminopropyl)-1*H*-indol-5-yl ester

Prepared from the product of Step A as described in Example 1, Step C: oil, 62% yield; ¹H NMR (CDCl₃) δ 8.1 (bs, 1H), 7.3 (d, J = 8 Hz, 1H), 7.2 (s, 1H), 7.0 (s, 1H), 6.85 (dd, J = 8, 2 Hz, 1H), 3.2 (m, 1H), 2.8 (dd, J = 14.2, 4.8 Hz, 1H), 2.62 (dd, J = 14.2, 6.0 Hz, 1H), 1.9 (m, 1H), 1.2 (m, 4H), 1.17 (d, J = 8 Hz, 3H); MS(ESI) *m/z* 259 (M + H)⁺.

EXAMPLE 5

Ingredients	Amount (wt %)
2,2-Dimethyl-propionic acid 3-(2-aminopropyl)-1 <i>H</i> -indol-5-yl ester	0.01 – 2%
Hydroxypropyl methylcellulose	0.5%
Dibasic sodium phosphate (anhydrous)	0.2%
Sodium chloride	0.5%
Disodium EDTA (Edetate disodium)	0.01%
Polysorbate 80	0.05%
Benzalkonium chloride	0.01%
Sodium hydroxide / Hydrochloric acid	For adjusting pH
Purified water	q.s. to 100%

10

EXAMPLE 6

Ingredients	Amount (wt %)
2,2-Dimethyl-propionic acid 3-(2-aminopropyl)-1 <i>H</i> -indol-5-yl ester	0.01 – 2%
Methyl cellulose	4.0%
Dibasic sodium phosphate (anhydrous)	0.2%
Sodium chloride	0.5%
Disodium EDTA (Edetate disodium)	0.01%
Polysorbate 80	0.05%
Benzalkonium chloride	0.01%
Sodium hydroxide / Hydrochloric acid	For adjusting pH
Purified water	q.s. to 100%

15

EXAMPLE 7

Ingredients	Amount (wt %)
Cyclopropanecarboxylic acid 3-(2-aminopropyl)-1 <i>H</i> -indol-5-yl ester	0.01 – 2%
Guar gum	0.4- 6.0%
Dibasic sodium phosphate (anhydrous)	0.2%-
Sodium chloride	0.5%
Disodium EDTA (Edetate disodium)	0.01%
Polysorbate 80	0.05%
Benzalkonium chloride	0.01%
Sodium hydroxide / Hydrochloric acid	For adjusting pH
Purified water	q.s. to 100%

EXAMPLE 8

Ingredients	Amount (wt %)
Cyclopropanecarboxylic acid 3-(2-aminopropyl)-1 <i>H</i> -indol-5-yl ester	0.01 – 2%
White petrolatum and mineral oil and lanolin	Ointment consistency
Dibasic sodium phosphate (anhydrous)	0.2%
Sodium chloride	0.5%
Disodium EDTA (Edetate disodium)	0.01%
Polysorbate 80	0.05%
Benzalkonium chloride	0.01%
Sodium hydroxide / Hydrochloric acid	For adjusting pH

EXAMPLE 9**Solution Stability Studies**

The solution stability of the example compounds were assessed using an accelerated stress test. The compound was dissolved in pH 5, 0.025 M sodium citrate buffer (5~15 µg/mL). In duplicate, 2 mL of each solution in a glass vial was heated at 75°C for 14 days. Samples were analyzed periodically using HPLC and % degradation was calculated for the sample. The predicted shelf life (25°C) was based on the loss of 10% compound (T₉₀) and the fact that the rate of degradation for a first order reaction decreased 50% for every 10°C drop in temperature.


Table 2. Compound Stability.

Example	Predicted Shelf Life, months
α -methylserotonin	2.6
1	1.32
2	3.36
3	11.3
4	5.81

5 The predicted shelf lives for representative compounds of Formula I are listed in Table 2. The parent compound, α -methylserotonin, and the corresponding propionic acid ester derivative (Example 1) are included for reference. Example 1, a straight chain alkyl ester, did not provide an increase in the stability of the parent compound. The other Examples in Table 1, more sterically hindered esters, were less susceptible than the parent compound to both oxidative degradation and ester
10 hydrolysis as illustrated by the decreased level of degradation observed under the experimental stress conditions.

We Claim:

1. A compound of the formula:



- wherein G is chosen from hydrogen, halogen, or C₁₋₄alkyl;
 R is chosen from C₃₋₆alkyl, C₃₋₆alkyl substituted with hydroxyl, CO(OC₁₋₄alkyl),
 CON(C₁₋₄alkyl)₂, or C₂₋₄alkenyl substituted by phenyl;
 R¹ is chosen from hydrogen, C₁₋₄alkyl;
 and pharmaceutically acceptable salts and solvates.

2. The compound of Claim 1 selected from the group consisting of:
 isobutyric acid 3-(2-aminopropyl)-1*H*-indol-5-yl ester;
 2,2-dimethyl-propionic acid 3-(2-aminopropyl)-1*H*-indol-5-yl ester; and
 cyclopropanecarboxylic acid 3-(2-aminopropyl)-1*H*-indol-5-yl ester.

3. The compound of Claim 2 that is 2,2-dimethyl-propionic acid 3-(2-aminopropyl)-1*H*-indol-5-yl ester.

4. A topical ophthalmic composition for lowering and controlling normal or elevated IOP, comprising a pharmaceutically effective amount of a compound of Claim 1.

5. A method for lowering and controlling normal or elevated IOP, which comprises administering a pharmaceutically effective amount of a compound of Claim 1.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/31144

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D209/16 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, BIOSIS, MEDLINE, EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 31354 A (KENNETT GUY ANTHONY ;SMITHKLINE BEECHAM PLC (GB)) 23 July 1998 (1998-07-23) cited in the application page 2, line 31	1-5
Y	WO 93 00333 A (SMITHKLINE BEECHAM PLC) 7 January 1993 (1993-01-07) cited in the application abstract; claims	1-5
Y	WO 94 03162 A (GLAXO GROUP LTD ;BIRCH PHILLIP JOHN (GB)) 17 February 1994 (1994-02-17) claims 3,4	1-5
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

27 February 2001

Date of mailing of the international search report

13/03/2001

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTI NATIONAL SEARCH REPORT

ational Application No
PCT/US 00/31144

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	OSBORNE N N ET AL: "DO BETA-ADRENOCEPTORS AND SEROTONIN 5-HT1A RECEPTORS HAVE SIMILAR FUNCTIONS IN THE CONTROL OF INTRAOCULAR PRESSURE IN THE RABBIT?" OPHTHALMOLOGICA,CH,KARGER, BASEL, vol. 210, 1996, pages 308-314, XP002051581 ISSN: 0030-3755 the whole document	1-5
Y	GUPTA Y K ET AL: "THERAPEUTIC POTENTIALS OF 5-HT RECEPTOR MODULATORS" INDIAN JOURNAL OF PHARMACOLOGY,XX,XX, vol. 26, no. 2, 1 June 1994 (1994-06-01), pages 94-107, XP000571272 ISSN: 0253-7613 page 102	1-5
Y	OSBORNE N N: "SEROTONIN AND MELATONIN IN THE IRIS/CILIARY PROCESSES AND THEIR INVOLVEMENT IN INTRAOCULAR PRESSURE" ACTA NEUROBIOLOGIAE EXPERIMENTALIS,PL,WARSZAW, vol. 54, no. SUPPL, 1994, pages 57-64, XP000878634 ISSN: 0065-1400 abstract	1-5
Y	ISMAIEL, ABD M. ET AL: "5-HT1 and 5-HT2 binding profiles of the serotonergic agents.alpha.-methylserotonin and 2-methylserotonin" J. MED. CHEM. (1990), 33(2), 755-8 , XP000876594 abstract	1-5
Y	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LYON, ROBERT A. ET AL: "Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens" retrieved from STN Database accession no. 109:47843 XP002161467 abstract & EUR. J. PHARMACOL. (1988), 145(3), 291-7	1-5
A,P	WO 00 16761 A (ALCON LAB INC ;DEAN THOMAS R (US); MAY JESSE A (US); SHARIF NAJAM) 30 March 2000 (2000-03-30) cited in the application the whole document	1-5

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 00/31144

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9831354	A	23-07-1998	NONE	
WO 9300333	A	07-01-1993	AT 172723 T	15-11-1998
			AU 1928892 A	25-01-1993
			CA 2110574 A	07-01-1993
			DE 69227458 D	03-12-1998
			DE 69227458 T	29-04-1999
			DK 593513 T	05-07-1999
			EP 0593513 A	27-04-1994
			IE 921993 A	30-12-1992
			JP 6508354 T	22-09-1994
			MX 9203050 A	01-07-1993
			PT 100603 A	31-08-1993
			US 5571833 A	05-11-1996
			ZA 9204523 A	20-12-1993
WO 9403162	A	17-02-1994	AU 4705193 A	03-03-1994
			EP 0655912 A	07-06-1995
			JP 7509476 T	19-10-1995
			US 5693654 A	02-12-1997
			ZA 9305522 A	13-06-1994
WO 0016761	A	30-03-2000	AU 6132699 A	10-04-2000

Form PCT/ISA/210 (patent family annex) (July 1992)